Can a drug for eczema soothe the agony of Post-Burn itch?
NCT ID NCT06226610
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether Dupixent, a drug already used for eczema and asthma, can reduce severe itching in adults with burn scars. About 46 participants will receive either Dupixent or a placebo injection every two weeks. The main goal is to see if itching scores drop significantly after 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dupilumab (Dupixent)
- What this could lead to
- If it works, this could provide a new treatment option for people suffering from persistent, severe itching after burn injuries.
- What could go wrong
- This is a small, early-phase trial with only 46 participants. It may not show a meaningful benefit over placebo, and results may not apply to all burn survivors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRURITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Akron Children's Hospital
RECRUITINGAkron, Ohio, 44308, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.